CEO Adar Poonawalla said on Thursday that the Serum Institute of India plans to launch a COVID-19 vaccine for Omicrons after six months.
Covavax vaccine data are available, he told reporters at an event.
There are good data on Covovax, the original Novovax vaccine, covering omicron. After six months, we’ll launch an Omicron-specific vaccine.
An Omicron-specific vaccine is being developed by the Pune-based Serum Institute in collaboration with US biotechnology giant Novavax.
As a result of its fast transmission and infection rate, the Omicron subvariant of COVID-19 was declared a variant of concern by the World Health Organisation.
Covavax is available in the country for those aged 12 and up.
According to Poonawalla, monkeypox vaccines are “debatable”.
The cases here created quite a buzz. We are conducting research on the topic and can collaborate with the Department of Biotechnology on it as well. We will see what happens in six months,” he said.